Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 1, 1998, Pages 52-57

  Eap, Chin B ^a   Schnyder, Christiane ^b   Besson, Jaques ^b   Savary, Line ^b   Buclin, Thierry ^b  

^a Hopital de Cery   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; CLOMETHIAZOLE; DIMETHYLNITROSAMINE DEMETHYLASE; DRUG METABOLITE; ESCOFLEX; UNCLASSIFIED DRUG;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER PROTECTION; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ALCOHOLISM; ANTICONVULSANTS; AREA UNDER CURVE; CHLORMETHIAZOLE; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL;

EID: 0031868634     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90022-4     Document Type: Article

References (23)

1. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4:168-79.
2. Valentine JL, Lee SST, Seaton MJ, Asgharian B, Farris G, Corton JC, et al. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. Toxicol Appl Pharmacol 1996;141:205-13.
3. Anundi I, Lähteenmäki T, Rundgren M, Moldeus P, Lindros KO. Zonation of acetaminophen metabolism and cytochrome-P450 2E1-mediated toxicity studied in isolated periportal and perivenous hepatocytes. Biochem Pharmacol 1993;45:1251-9.
4. Kharasch ED, Thummel KE, Mautz D, Bosse S. Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther 1994;55:434-40.
5. Lieber CS. Biochemical and molecular basis of alcohol-induced injury to liver and other tissues. N Engl J Med 1988;319:1639-50.
6. Ingelman-Sundberg M, Johansson I, Yin H, Terelius Y, Eliasson E, Clot P, et al. Ethanol-inducible cytochrome P4502E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol 1993;10:447-52.
7. Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990;3:566-73.
8. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994;47:1503-8.
9. Zand R, Nelson SD, Slattery JT, Thummel KE, Kalhorn TF, Adams SP, et al. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993;54:142-9.
10. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994;56:359-67.
11. Carrière V, Goasduff T, Ratanasavanh D, Morel F, Gautier JC, Guillouzo A, et al. Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 1993;6:852-7.
12. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995;5:143-50.
13. Gorski JC, Jones DR, Wrighton SA, Hall SD. Contribution of human CYP3 A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 1997;27:243-56.
14. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2El. Clin Pharmacol Ther 1993;53:643-50.
15. Chen L, Mohr SN, Yang CS. Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers. Clin Pharmacol Ther 1996;60:651-60.
16. Hu Y, Mishin V, Johansson I, von Bahr C, Cross A, Ronis MJ, et al. Chlormethiazole as an efficient inhibitor of cytochrome P450 2El expression in rat liver. J Pharmacol Exp Ther 1994;269:1286-91.
17. Hoensch HP. Effect of chlormethiazole on the hepatic monooxygenase enzyme system. Acta Psychiatr Scand 1986;73:66-8.
18. Majumdar SK. Chlormethiazole: current status in the treatment of the acute ethanol withdrawal syndrome. Drug Alcohol Depend 1990;27:201-7.
19. Eap CB, Schnyder C, Savary L. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sei Appl 1998;705:139-44.
20. Desiraju RK, Renzi NL Jr, Nayak RK, Ng KT. Pharmacokinetics of chlorzoxazone in humans. J Pharm Sci 1983;72:991-4.
21. Lucas D, Ménez C, Girre C, Bodénez P, Hispard E, Ménez JF. Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. Alcohol Clin Exp Res 1995;19:362-6.
22. Gebhardt AC, Lucas D, Menez JF, Seitz H. Chlormethiazole inhibition of cytochrome P4502E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology 1997;26:957-61.
23. Kim ND, Kwak MK, Kim SG. Inhibition of cytochrome P450 2E1 expression by 2-(allylthio)pyrazine, a potential chemoprotective agent: hepatoprotective effects. Biochem Pharmacol 1997;53:261-9.